IRulya Therapeutics IRLA
NASDAQ IRLA
$33.78 +2.78 (+8.95%)
At close: Nov 9, 2026 · 4:00 PM EST

IRulya Therapeutics (IRLA) Gains from Sales and Divestitures (2022 - 2023)

Updated

IRulya Therapeutics (IRLA) reported Gains from Sales and Divestitures of $34,000 for Q4 2023, compared with -$17,000 a year earlier and up 325.0% from the prior quarter.

Analysis

IRulya Therapeutics (IRLA) Gains from Sales and Divestitures (2022 - 2023) Analysis & Trends

For FY2023, IRulya Therapeutics posted Gains from Sales and Divestitures of -$37,000.

  • By year, Gains from Sales and Divestitures came in at -$94,000 in FY2022.
  • Per Business Quant data, the three quarters before Q4 2023 came in at $8,000 (Q3 2023), -$6,000 (Q2 2023) and -$73,000 (Q1 2023).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,261.99 Bn 1,235.61 Bn 20.46 Bn
2 Johnson & Johnson 678.93 Bn 598.79 Bn 17.30 Bn
3 AbbVie 518.29 Bn 486.30 Bn 13.12 Bn
4 Merck 365.98 Bn 328.92 Bn 13.19 Bn
5 Novartis Ag 316.85 Bn 290.09 Bn -
6 Astrazeneca 293.40 Bn 267.29 Bn 13.26 Bn
7 Amgen 251.78 Bn 203.43 Bn 7.58 Bn
8 Gilead Sciences 210.61 Bn 185.71 Bn 6.73 Bn
9 Pfizer 166.87 Bn 114.23 Bn 12.56 Bn
10 IRulya Therapeutics 207.35 Mn 91.35 Mn -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2023 34,000.00
Sep 30, 2023 8,000.00
Jun 30, 2023 -6,000.00
Mar 31, 2023 -73,000.00
Dec 31, 2022 -17,000.00
Jun 30, 2022 -77,000.00
API Access

IRulya Therapeutics Gains from Sales and Divestitures API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=gains-from-sales-and-divestitures&ticker=IRLA&period=max&api_key=YOUR_API_KEY